Every 10-Q that Tela Bio, Inc. (TELA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TELA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TELA filings page.
TELA Bio, Inc., a commercial-stage medtech company focused on soft-tissue reconstruction, reported relatively flat revenue but widening losses for the quarter and six months ended June 30, 2026. Quarterly revenue was $19.3 million, down 4% year over year, and first-half revenue was $38.4 million, down 1%. OviTex hernia products grew in unit volume, but OviTex PRS plastic/reconstructive products declined and U.S. price/mix shifted toward smaller, lower-priced units.
Net loss increased to $11.3 million for the quarter and $23.5 million year-to-date, driven partly by higher interest expense after refinancing into a $60 million Perceptive term loan. Gross margin improved to 72% in the quarter. Cash and cash equivalents fell to $30.4 million, and the company reported stockholders’ deficit of $15.9 million.
Management disclosed that forecasts indicate probable noncompliance with minimum revenue covenants under the Perceptive Credit Agreement within 12 months and highlighted sensitivity to a $5 million minimum liquidity covenant. These factors, combined ongoing operating losses and limited liquidity to repay accelerated debt, led to a conclusion that substantial doubt exists about the company’s ability to continue as a going concern. Management is pursuing covenant waivers or amendments, revenue initiatives, and cost reductions while also maintaining a $50 million at-the-market equity program with no sales to date.
TELA Bio reported Q1 2026 revenue of $19.1 million and a net loss of $12.3 million. Revenue grew about 3% from the prior-year quarter, driven mainly by higher OviTex unit sales and stronger international demand, partly offset by weaker price mix and slightly lower OviTex PRS volume.
Gross margin slipped to 66% from 68% as higher excess and obsolete inventory charges offset revenue growth. Operating expenses were roughly flat overall, with modestly lower sales and marketing and research and development, and higher general and administrative costs.
The company posted operating cash outflows of $11.2 million and ended the quarter with $39.5 million of cash and cash equivalents. Long‑term debt under its Perceptive term loan remained at $60.0 million, and accumulated deficit increased to $409.8 million, resulting in a stockholders’ deficit of $5.2 million.
TELA Bio, Inc. filed its quarterly report, showing higher sales and a narrower loss. Revenue for Q3 2025 reached $20.7 million, up 9% from $19.0 million a year ago, with gross margin steady at 68%. The company reported a net loss of $8.6 million for the quarter, an improvement from a $10.4 million loss in Q3 2024. For the first nine months of 2025, revenue was $59.4 million versus $51.7 million in 2024, while net loss was $29.8 million compared to $28.6 million, which included a prior-year gain on a product line sale.
Cash and cash equivalents were $29.7 million as of September 30, 2025, down from $52.7 million at year-end, driven by operating cash outflows of $23.3 million year‑to‑date. Long-term debt was $41.5 million. Subsequent to quarter‑end, TELA closed a new credit facility of up to $70.0 million with Perceptive, including an initial $60.0 million draw used in part to repay its MidCap loan; the facility bears interest at 7.85% plus the greater of one‑month Term SOFR or 4.25% and is interest‑only until November 14, 2030. The company also entered an underwriting agreement for an underwritten registered direct offering of 4,189,000 shares at $1.11 per share and pre‑funded warrants for 7,523,000 shares at $1.1099 per warrant, for expected gross proceeds of approximately $13.0 million, subject to customary closing conditions.
TELA Bio reported continued commercial growth with revenue of $20.2 million for the quarter ended June 30, 2025, a 26% increase from $16.1 million a year earlier, and $38.7 million for the six months, up 18% year-over-year. Gross profit for the quarter was $14.1 million. Quarterly net loss narrowed to $9.9 million (EPS -$0.22) from $12.6 million, while the six-month net loss was $21.2 million versus $18.3 million, noting the prior-year six-months included a $7.6 million gain on the sale of the NIVIS product line.
Balance sheet and liquidity show $34.98 million in cash and cash equivalents (restricted cash brings cash per statements of cash flows to $35.24 million), total assets of $67.54 million and total liabilities of $58.35 million. The company carries total debt of $41.38 million (long-term portion $38.05 million) under a MidCap term loan maturing in 2027 with covenants including minimum net revenue tests. Product mix for the quarter was $12.49 million OviTex and $7.33 million OviTex PRS, with international sales of $3.0 million. The company discloses an accumulated deficit of $379.9 million and says it expects to incur losses for the foreseeable future.